Pre-made Simridarlimab benchmark antibody ( Whole mAb, anti-CD47;CD274/PD-L1 therapeutic antibody, Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Simridarlimab biosimilar, Whole mAb, Anti-CD47;CD274/PD-L1 Antibody: Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-693-1mg	1mg	Inquiry
GMP-Bios-ab-693-10mg	10mg	Inquiry
GMP-Bios-ab-693-100mg	100mg	Inquiry
GMP-Bios-ab-693-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Simridarlimab biosimilar, Whole mAb, Anti-CD47;CD274/PD-L1 Antibody: Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody
INN Name	Simridarlimab
Target	CD47;PD-L1
Format	Bispecific Mixed mAb/VH-VH-CH2-CH3
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1;IgG1
VD LC	Kappa;na
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2021
Year Recommended	na
Companies	Innovent Biologics
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na